These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 12938075)

  • 41. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition.
    Lopez OL; Becker JT; Saxton J; Sweet RA; Klunk W; DeKosky ST
    J Am Geriatr Soc; 2005 Jan; 53(1):83-7. PubMed ID: 15667381
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cholinesterase inhibitors in the treatment of Alzheimer's disease and related dementias.
    Masterman D
    Clin Geriatr Med; 2004 Feb; 20(1):59-68. PubMed ID: 15062487
    [No Abstract]   [Full Text] [Related]  

  • 43. [Factors that modify the natural course of Alzheimer's disease].
    López OL; Becker JT
    Rev Neurol; 2003 Jul 16-31; 37(2):149-55. PubMed ID: 12938075
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
    Cortes F; Portet F; Touchon J; Vellas B
    J Nutr Health Aging; 2007; 11(4):330-7. PubMed ID: 17653493
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Strategies for the treatment of Alzheimer's disease. The 'ad continuum' concept].
    Boada Rovira M
    Rev Neurol; 2001 Jun 1-15; 32(11):1074-84. PubMed ID: 11562834
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Medical treatment of Alzheimer's disease].
    López-Pousa S; Serra-Mestres J
    Rev Neurol; 1998 Jun; 26(154):1054-60. PubMed ID: 9658492
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
    Cacabelos R
    Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Therapy in Alzheimer disease].
    Kovács T
    Orv Hetil; 2004 Apr; 145(17):925-8. PubMed ID: 15170971
    [No Abstract]   [Full Text] [Related]  

  • 49. Alzheimer's disease drugs: an application of the hormetic dose-response model.
    Calabrese EJ
    Crit Rev Toxicol; 2008; 38(5):419-51. PubMed ID: 18568864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis.
    Harry RD; Zakzanis KK
    Hum Psychopharmacol; 2005 Apr; 20(3):183-7. PubMed ID: 15700322
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The neurobiology of neuropsychiatric syndromes in dementia.
    Meeks TW; Ropacki SA; Jeste DV
    Curr Opin Psychiatry; 2006 Nov; 19(6):581-6. PubMed ID: 17012935
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.